1. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo
- Author
-
Ogura Y, M Hakozaki, Kunitaka Hirose, Takafumi Noma, Norio Iizuka, Takashi Suzuki, E Inoguchi, Masaaki Oka, Shouichi Hazama, Kiyoshi Yoshimura, and F Wang
- Subjects
Cancer Research ,Cellular immunity ,in vivo animal models ,medicine.medical_treatment ,Biology ,Transfection ,Mice ,Immune system ,medicine ,Animals ,Humans ,tumour immunity ,Fibrosarcoma ,Interleukin-15 ,Mice, Inbred BALB C ,Genetic transfer ,Regular Article ,Genetic Therapy ,Neoplasms, Experimental ,medicine.disease ,vaccination ,gene therapy ,Cytokine ,Oncology ,IL-15 ,Interleukin 15 ,Immunology ,Cancer research ,Female ,CD8 - Abstract
We examined the effect of interleukin-15 (IL-15) gene transfer into tumour cells on the host's anti-tumour response. In BALB/c mice IL-15 producing Meth-A cells (Meth-A/IL-15) underwent complete rejection, in a response characterized by massive infiltration of CD4+ T-cells and neutrophils. In contrast, Meth-A cells transfected with vector alone (Meth-A/Neo) grew rapidly. Moreover, rechallenged parental cells also were rejected in association with CD8+ T-cell infiltration. However, in nude mice there was no drastic difference between Meth-A/IL-15 and Meth-A/Neo cells. These results demonstrate that IL-15-secreting tumour cells can stimulate local and systemic T-cell-dependent immunity and therefore may have a potential role in cancer therapy. © 1999 Cancer Research Campaign
- Published
- 1999